News

Nearly 65% of responders say their migraine disease makes them feel like life is passing them by and more than half claimed they cannot make plans with friends or family because of the unpredictability of their disease.

The assistant professor of neurology at the Keck School of Medicine at University of Southern California shared her insight into the study data and the therapy’s potential advantages for patients with Parkinson disease.

Here's what is coming soon to NeurologyLive.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed populations that exhibit greater practice effects than others.

The 2 organizations will use whole-genome sequencing and clinical characterization to investigate the genetic causes of CP.

Future steps, including plans for global studies, are currently being evaluated by Biogen, with the final results from the phase 2a study expected to be released in an upcoming scientific forum.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed why gaps remain in screening for patients with Parkinson disease who may be eligible for device-aided therapies.

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Neurology News Network for the week ending May 15, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.

The neurologist from Cleveland Clinic stressed the potential for responsive neurostimulation in older populations with epilepsy and the need for expanded research.

African Americans are not only at increased risk of having a stroke, but they're also at increased risk of being debilitated by or dying from a stroke.

Data presented at the ASGCT 2021 meeting showed increased microdystrophin expression with SGT-001.

Neal Parikh, MD, discussed the inconsistencies with access to treatment regimens aimed at improving smoking cessation in post-stroke patients.

Among early-treated patients, in the door-to-puncture time interval, each 1 hour of delay was associated with 0.92 health life-years lost and each 1 second of delay with 2.2 health life-hours lost.

Northwell Health will conduct a NIH-funded study assessing the effects of the experimental drug in treating patients with ICH.

The director of the sleep disorders center at Cleveland Clinic discussed the data on lower sodium oxybate presented at AAN 2021.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed the aim of his practice’s study.

All patients treated with ocrelizumab (Ocrevus; Genentech) were B-cell depleted and had lower SARS-CoV-2 antibody response than any other patients in the study.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed her recently published paper that called for progressive MS research.

The safety profile of the SLC13A5 vector was “excellent” according to study authors, with no adverse effects on weight, general activity, or survival in knockout mice and wild type littermates.

In addition to comorbidity frequency, the researchers also studied the comparison of comorbidities between men and women with migraine.

The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients.

The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.

Understanding the signs and symptoms stroke during National Stroke Awareness Month.

Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).

A poster presentation at the American Psychiatric Association Virtual Meeting suggests that late-life depression might predict self-reported cognitive complaints.

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.